Responsible nanotechnology development

Nanotechnologies have an increasing relevance in our life, numerous products already on the market are associated with this new technology. Although the chemical constituents of nanomaterials are often well known, the properties at the nano level are completely different from the bulk materials. Independently from the specific application the knowledge in this field involves different type of scientific competence. The accountability of the nanomaterial research imply the parallel development of innovative methodological approaches to assess and manage the risks associated to the exposure for humans and environmental to the nanomaterials for their entire life-cycle: production, application, use and waste discharge. The vast numbers of applications and the enormous amount of variables influencing the characteristics of the nanomaterials make particularly difficult the elaboration of appropriate nanotoxicological protocols. According to the official declarations exist an awareness of the public institutions in charge of the regulatory system, about the environmental, health and safety implications of nanotechnology, but the scientific information is insufficient to support appropriate mandatory rules. Public research programmers must play an important role in providing greater incentives and encouragement for nanotechnologies that support sustainable development to avoid endangering humanity’s well being in the long-term. The existing imbalance in funds allocated to nanotech research needs to be corrected so that impact assessment and minimization and not only application come high in the agenda. Research funding should consider as a priority the elimination of knowledge gaps instead of promoting technological application only. With the creation of a public register collecting nanomaterials and new applications it is possible, starting from the information available, initiate a sustainable route, allowing the gradual development of a rational and informed approach to the nanotoxicology. The establishment of an effective strategy cannot ignore the distinction between different nanoparticles on their use and the type of exposure to which we are subjected. Categorization is essential to orchestrate toxicological rules realistic and effective. The responsible development of nanotechnology means a common effort, by scientists, producers, stakeholders, and public institutions to develop appropriate programs to systematically approach the complex issue of the nanotoxicology.

[1]  Stephen M. Roberts,et al.  Characterization of Nanomaterials for Toxicological Evaluation , 2009 .

[2]  Igor Linkov,et al.  Emerging methods and tools for environmental risk assessment, decision-making, and policy for nanomaterials: summary of NATO Advanced Research Workshop , 2008, Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology.

[3]  D. Tomalia Dendrons/dendrimers: quantized, nano-element like building blocks for soft-soft and soft-hard nano-compound synthesis , 2010 .

[4]  Maria Dusinska,et al.  Testing strategies for the safety of nanoparticles used in medical applications. , 2009, Nanomedicine.

[5]  William A. Goddard,et al.  Handbook of Nanoscience, Engineering, and Technology , 2002 .

[6]  Mihail C. Roco,et al.  National Nanotechnology Initiative - Past, Present, Future , 2007 .

[7]  Lang Tran,et al.  Safe handling of nanotechnology , 2006, Nature.

[8]  Ruchika Nijhara,et al.  Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. , 2006, Nanomedicine : nanotechnology, biology, and medicine.

[9]  Andrew D. Maynard,et al.  Don't define nanomaterials , 2011, Nature.

[10]  Steffen Foss Hansen,et al.  Late lessons from early warnings for nanotechnology. , 2008, Nature nanotechnology.

[11]  R. Kannan,et al.  Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. , 2010, Drug discovery today.

[12]  N. Rosato,et al.  Public optimism towards nanomedicine , 2011, International journal of nanomedicine.

[13]  G. Oberdörster,et al.  Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles , 2005, Environmental health perspectives.

[14]  R. Hurt,et al.  Nanotoxicology: the asbestos analogy revisited. , 2008, Nature nanotechnology.

[15]  Christy L. Haynes,et al.  Functional assessment of metal oxide nanoparticle toxicity in immune cells. , 2010, ACS nano.

[16]  K. Mizuno,et al.  Pulmonary toxicity of well-dispersed multi-wall carbon nanotubes following inhalation and intratracheal instillation , 2012, Nanotoxicology.

[17]  K. Mizuno,et al.  Pulmonary toxicity of well-dispersed single-wall carbon nanotubes after inhalation , 2012, Nanotoxicology.

[18]  T. Xia,et al.  Toxic Potential of Materials at the Nanolevel , 2006, Science.

[19]  W. Liu,et al.  Impact of silver nanoparticles on human cells: Effect of particle size , 2010, Nanotoxicology.

[20]  Maurizio Chiriva-Internati,et al.  Nanotechnology and human health: risks and benefits , 2010, Journal of applied toxicology : JAT.

[21]  A. Stirling,et al.  Opening Up the Politics of Knowledge and Power in Bioscience , 2012, PLoS biology.

[22]  M. Kandlikar,et al.  The impact of toxicity testing costs on nanomaterial regulation. , 2009, Environmental science & technology.

[23]  Chris Toumey,et al.  Democratizing nanotech, then and now. , 2011, Nature nanotechnology.

[24]  Steffen Foss Hansen,et al.  Categorization framework to aid hazard identification of nanomaterials , 2007 .

[25]  Antonio Nunes,et al.  Length-dependent retention of carbon nanotubes in the pleural space of mice initiates sustained inflammation and progressive fibrosis on the parietal pleura. , 2011, The American journal of pathology.

[26]  Paul A Schulte,et al.  Medical surveillance, exposure registries, and epidemiologic research for workers exposed to nanomaterials. , 2010, Toxicology.

[27]  Donald A. Tomalia,et al.  In quest of a systematic framework for unifying and defining nanoscience. , 2012, Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology.

[28]  Saber M Hussain,et al.  Surface charge of gold nanoparticles mediates mechanism of toxicity. , 2011, Nanoscale.

[29]  Yinfa Ma In Vitro Models for Nanotoxicity Testing , 2009 .

[30]  Serdar Durdagi,et al.  In Silico Drug Screening Approach for the Design of Magic Bullets: A Successful Example with Anti-HIV Fullerene Derivatized Amino Acids , 2009, J. Chem. Inf. Model..

[31]  The complexity of public engagement. , 2012, Nature nanotechnology.

[32]  Robert Langer,et al.  On firm ground: IP protection of therapeutic nanoparticles , 2010, Nature Biotechnology.

[33]  M. Moore,et al.  Do nanoparticles present ecotoxicological risks for the health of the aquatic environment? , 2006, Environment international.

[34]  David Schneider,et al.  Toxicity of gold-nanoparticles: Synergistic effects of shape and surface functionalization on micromotility of epithelial cells , 2011, Nanotoxicology.

[35]  Bengt Fadeel,et al.  Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. , 2010, Advanced drug delivery reviews.

[36]  Konrad Hungerbühler,et al.  Potential exposure of German consumers to engineered nanoparticles in cosmetics and personal care products , 2011, Nanotoxicology.

[37]  Serdar Durdagi,et al.  3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[38]  M. McCall,et al.  Environmental, health and safety issues: Nanoparticles in the real world. , 2011, Nature nanotechnology.

[39]  Gibson Peter,et al.  Considerations on a Definition of Nanomaterial for Regulatory Purposes , 2010 .

[40]  Jim Willis,et al.  Science policy considerations for responsible nanotechnology decisions. , 2011, Nature nanotechnology.

[41]  M. Prato,et al.  Fullerene derivatives: an attractive tool for biological applications. , 2003, European journal of medicinal chemistry.

[42]  B. Fadeel,et al.  In search of the Holy Grail: Folate-targeted nanoparticles for cancer therapy. , 2011, Biochemical pharmacology.

[43]  David Gee,et al.  Late Lessons from Early Warnings: Towards realism and precaution with EMF? , 2009, Pathophysiology : the official journal of the International Society for Pathophysiology.

[44]  Jerzy Leszczynski,et al.  Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles. , 2011, Nature nanotechnology.

[45]  Geoffrey L. Cohen,et al.  Cultural cognition of the risks and benefits of nanotechnology. , 2009, Nature nanotechnology.

[46]  David B Warheit,et al.  Pulmonary bioassay studies with nanoscale and fine-quartz particles in rats: toxicity is not dependent upon particle size but on surface characteristics. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  Mihail C Roco,et al.  Nanotechnology's future. , 2006, Scientific American.